2013
Latent Tuberculosis Infection: Screening and Treatment in an Urban Setting
Morano JP, Walton MR, Zelenev A, Bruce RD, Altice FL. Latent Tuberculosis Infection: Screening and Treatment in an Urban Setting. Journal Of Community Health 2013, 38: 941-950. PMID: 23728822, PMCID: PMC3781590, DOI: 10.1007/s10900-013-9704-y.Peer-Reviewed Original ResearchConceptsIsoniazid preventative therapyLatent tuberculosis infectionTuberculin skin testSelf-administered therapyActive tuberculosisRecent incarcerationNew latent tuberculosis infectionsPositive tuberculin skin testMobile outreach clinicHigh tuberculosis prevalenceMultivariate logistic regressionInner-city populationDOT participantsLTBI treatmentObserved therapyTuberculosis infectionPreventative therapySkin testChest radiographsTuberculosis prevalenceOutreach clinicsCXR screeningHealthcare clinicsYounger ageSimilar outcomes
2012
Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication
Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication. The American Journal Of Drug And Alcohol Abuse 2012, 38: 206-212. PMID: 22242700, PMCID: PMC5573865, DOI: 10.3109/00952990.2011.643975.Peer-Reviewed Original ResearchConceptsSustained virologic responseEarly virologic responseMethadone maintenance treatmentHepatitis C treatmentSelf-administered therapyHepatitis C virusHCV treatmentVirologic responseAdherence supportWeek 12HCV treatment adherenceOpioid-dependent patientsBlood-borne infectionsMethadone-maintained patientsCompletion of treatmentCase-control studyMethadone maintenance clinicsMethadone maintenance programMental illness comorbidityConcurrent substance useC treatmentObserved therapyHCV genotypesHIV statusIllness comorbidity
2011
Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes
Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials 2011, 33: 436-444. PMID: 22101218, PMCID: PMC3268833, DOI: 10.1016/j.cct.2011.11.002.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesSelf-administered therapyAntiretroviral therapyTreatment outcomesViral loadEvidence-based adherence interventionsPoor HIV treatment outcomesGenotypic resistance testingMedication-assisted treatmentDSM-IV criteriaAlcohol use disorderCase management servicesViral suppressionPrimary outcomeOpioid dependenceAdherence interventionsCD4 testingIntervention periodStudy groupEligibility criteriaUse disordersIntervention monthDrug usersAdverse HIVHIV
2009
Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy
Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009, 21: 976-983. PMID: 20024753, PMCID: PMC2797133, DOI: 10.1080/09540120802657555.Peer-Reviewed Original ResearchConceptsInjection drug usersCES-D scoresMajor depressive disorderAntiretroviral therapyCD4 countDepressive symptomsDrug usersDrug useHIV-1 RNA levelsProspective clinical trialsSubstance abuse treatment servicesSelf-administered therapyActive drug useNon-Caucasian raceSix-month followSix-month dataAntidepressant medicationAntiretroviral treatmentPoor adherenceSymptomatic responseMale genderClinical trialsDepressive disorderDepression ScaleDrug treatmentPersistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial
Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 176-181. PMID: 19131891, PMCID: PMC2670996, DOI: 10.1097/qai.0b013e3181938e7e.Peer-Reviewed Original ResearchConceptsSelf-administered therapyHIV-1 RNACD4 lymphocyte countVirological successDrug usersAntiretroviral therapyLymphocyte countMonths postinterventionLog10 HIV-1 RNAProportion of subjectsActive drug usersVirological benefitVirological outcomesSecondary outcomesControlled TrialsPrimary outcomeBlood samplesDAARTMultivariate analysisBenefits persistTherapyTrialsAdditional strategiesOutcomesPostintervention
2007
Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy
Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS And Behavior 2007, 12: 284-293. PMID: 18085432, PMCID: PMC2693908, DOI: 10.1007/s10461-007-9336-2.Peer-Reviewed Original ResearchConceptsSelf-administered therapyAntiretroviral therapyDrug usersComposite adherence scorePresence of depressionDrug treatment programsControlled TrialsSix-month periodAdherence scoreOwn medicationsHealth outcomesDAARTMajor causeTherapyAdherenceDiscontinuationHIVSuccessful program designTrialsParticipantsHospitalizationMedicationsLack of willingnessVisitsDirectly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance
Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsNew drug resistance mutationsSelf-administered therapyDrug usersAntiretroviral therapyHIV genotypic resistance testingFuture drug optionsAntiretroviral drug resistanceGenotypic resistance testingGenotypic sensitivity scoreMain outcome measuresMedication resistanceModified intentionVirologic benefitAntiretroviral resistanceTreat analysisClinical outcomesDrug mutationsDrug optionsOutcome measuresAdjusted probabilityDrug resistanceResistance mutationsHIVEffective interventionsSuperiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean change
2006
Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users
Smith-Rohrberg D, Mezger J, Walton M, Bruce RD, Altice FL. Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s48-s53. PMID: 17133204, DOI: 10.1097/01.qai.0000248338.74943.85.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsVirologic outcomesCase management servicesDrug usersVirologic successService utilizationRNA levelsHigher medical service utilizationHIV-1 RNA reductionLog10 HIV-1 RNAAntiretroviral Therapy (SMART) trialImproved virologic outcomesHealth service utilizationHIV-1 RNASelf-administered therapyCopies/mLMedical service utilizationActive drug usersSubstance abuse servicesAntiretroviral therapyHIV outcomesPrimary outcomeProblematic adherenceTherapy trialsDAART
2005
18 Management of HIVIAIDS in Correctional Settings
Altice F, Springer S. 18 Management of HIVIAIDS in Correctional Settings. 2005, 449-487. DOI: 10.1016/b978-012465271-2/50021-2.Peer-Reviewed Original ResearchClean injection equipmentHepatitis virus BHepatitis virus CPrevalence of HIVSelf-administered therapyArea of HIVSyringe exchange programsGeneral U.S. populationCorrectional settingsObserved therapyHIV infectionHIV medicationsComorbid conditionsMethadone maintenanceOwn medicationsSyringe exchangeNew casesVirus CCommunity settingsMedicationsHIVInformed consentExtensive involvementVirus BU.S. population
2004
Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical services